US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08/2026 22:37
US FDA approves Takeda, Protagonist's drug for rare blood cancer Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical 4502.T and Protagonist Therapeutics PTGX.O to treat a rare blood cancer, the health regulator said on Friday.
(Reporting by Kamal Choudhury, Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler